Malaysia gives conditional okay for use of Covid-19 treatment from Regeneron-Roche

Medical workers at the Covid-19 testing centre in Kuala Lumpur Hospital, on Feb 16, 2021. PHOTO: REUTERS

KUALA LUMPUR (REUTERS, THE STAR/ASIA NEWS NETWORK) - Malaysia's Health Ministry said on Tuesday (Dec 14) it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron and Roche, to treat Covid-19.

It has also approved a request from Merck & Co for a clinical trial import licence for its Covid-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.

"Ronapreve is indicated for the treatment of Covid-19 in adults and adolescents aged 12 years and older and weighing at least 40kg who do not require supplemental oxygen for Covid-19 and who are at increased risk of progressing to severe Covid-19," said health director-general Noor Hisham Abdullah in the statement.

He said the decision on using the drug was made at the 37th Drug Control Authority meeting on Monday.

Join ST's Telegram channel here and get the latest breaking news delivered to you.